专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20040191315A1 Office products containing antimicrobial agent 审中-公开
标题翻译：办公用品含抗菌剂
公开(公告)号：US20040191315A1
公开(公告)日：2004-09-30
申请号：US10410183
申请日：2003-04-10
发明人： Mike Slattery , Carl Froelich , Peter Adams , Robin McLaughlin , Cece Regal-Maxson
IPC分类号： A61K031/53 , A61K031/4162 , A61K009/14
CPC分类号： A01N25/34 , A01N59/00 , A61K31/4162 , A61K31/53 , A01N2300/00
摘要： An office product which has at least one exposed surface that is subject to infectious microorganisms, and an antimicrobial agent associated with the exposed surface to render ineffective or destroy infectious microorganisms. The antimicrobial agent may be present on the exposed surfaces of the office product as a coating, or as an integral part of a material used to form the exposed surface(s) of the office product. The antimicrobial agent is ineffective until activated using. Preferably, the antimicrobial agent is an amine which can be activated by a halogen. The present invention also relates to a process of making an infectious microorganism resistant office product which comprises providing the office product with an antimicrobial agent.
摘要翻译：具有至少一个受感染性微生物暴露的表面的办公用品，以及与暴露表面相关联的抗微生物剂，使其无效或破坏感染性微生物。抗微生物剂可以作为涂层存在于办公室产品的暴露表面上，或作为用于形成办公用品的暴露表面的材料的组成部分。抗菌剂无效，直到活化使用。优选地，抗微生物剂是可以被卤素活化的胺。本发明还涉及制备感染性微生物抗性办公室产品的方法，其包括向办公室产品提供抗微生物剂。

2. 发明申请

US20040171634A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use 有权
标题翻译：吲唑化合物和抑制蛋白激酶的药物组合物及其使用方法
公开(公告)号：US20040171634A1
公开(公告)日：2004-09-02
申请号：US10326755
申请日：2003-02-13
发明人： Robert Steven Kania , Steven Lee Bender , Allen J. Borchardt , Stephan James Cripps , Ye Hua , Michael David Johnson , Theodore Otto Johnson JR. , Hiep The Luu , Cynthia Louise Palmer , Siegfried Heinz Reich , Anna Maria Tempczyk-Russell , Min Teng , Christine Thomas , Michael David Varney , Michael Brennan Wallace , Michael Raymond Collins
IPC分类号： C07D471/02 , A61K031/4745 , A61K031/4162
CPC分类号： C07D401/12 , C07D209/18 , C07D401/14 , C07D403/12
摘要： Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
摘要翻译：描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号转导，从而调节和/或抑制不期望的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及治疗与不需要的血管生成和/或细胞增殖相关的癌症和其它疾病状态的方法，例如糖尿病性视网膜病变，新生血管性青光眼，类风湿性关节炎和银屑病，通过施用有效量的这种化合物。

3. 发明申请

US20040082542A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents 有权
标题翻译：唑衍生物和稠合双环唑衍生物作为治疗剂
公开(公告)号：US20040082542A1
公开(公告)日：2004-04-29
申请号：US10382203
申请日：2003-03-05
发明人： Adnan M.M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi S. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
IPC分类号： A61K031/695 , A61K031/4709 , A61K031/517 , A61K031/519 , A61K031/426 , A61K031/422 , A61K031/4162
CPC分类号： C07D233/64 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/18 , C07D235/30 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/12 , C07D453/02
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, null-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
摘要翻译：本发明提供某些化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。本发明的化合物可用作晚期糖基化终产物（RAGE）的受体与其配体如晚期糖基化终产物（AGE），S100 /钙粒蛋白/ EN-RAGE，β-淀粉样蛋白和两性蛋白之间相互作用的调节剂，以及由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，例如血管通透性增加，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍和肿瘤侵袭和转移。

4. 发明申请

US20030211045A1 Magnetoliposome composition for targeted treatment of biological tissue and associated methods 审中-公开
标题翻译：用于靶向治疗生物组织的磁性体脂质体组合物及相关方法
公开(公告)号：US20030211045A1
公开(公告)日：2003-11-13
申请号：US10182992
申请日：2002-12-13
发明人： Danuta Leszcyznska , Jerzy Leszczynski , Melania Babincova , Peter Babinec
IPC分类号： A61K049/00 , A61K038/38 , A61K038/17 , A61K031/716 , A61K031/715 , A61K039/395 , A61K031/4162 , A61K009/127
CPC分类号： A61K9/0009 , A61K9/127 , A61K41/0052
摘要： A composition for treatment of biological tissue responsive to a an applied magnetic field comprises a plurality of magnetoliposomes, each magnetoliposome of the plurality having a lipid-containing wall defining a vesicle, and a plurality of subdomain superparamagnetic particles, and an inactive prodrug capable of activating into a drug effective for treatment of the biological tissue, the prodrug carried by the plurality of magnetoliposomes for delivery to the biological tissue. A method of treatment for a biological tissue comprises administering the composition to the tissue, concentrating the plurality of magnetoliposomes in the biological tissue responsive to a substantially constant magnetic field, activating the inactive prodrug into an effective drug by applying an electromagnetic field to the concentrated plurality of magnetoliposomes so as to therein generate heat sufficient for activation without appreciable rupture of individual magnetoliposomes of the plurality of magnetoliposomes, and releasing the activated effective drug into the biological tissue by sufficiently increasing permeability of the lipid-containing walls of individual magnetoliposomes of the plurality of magnetoliposomes to thereby release activated drug.
摘要翻译：用于治疗施加的磁场的生物组织的组合物包括多个磁胶体，多个磁性脂质体具有限定泡囊的含脂质的壁，以及多个亚结构域的超顺磁性颗粒，以及能够活化的无活性前药成为有效治疗生物组织的药物，由多个磁胶体携带的前体药物用于递送至生物组织。用于生物组织的治疗方法包括将组合物施用于组织，响应于基本上恒定的磁场将多种磁胶体浓缩在生物组织中，通过向浓缩的多个元件施加电磁场将非活性前药活化成有效药物的磁性脂质体，以便在其中产生足够的活化热量，而不会明显破坏多个磁性脂质体的单个磁性脂质体，并且通过充分增加多个磁性脂质体中各个磁性脂质体的含脂质壁的渗透性，将活化的有效药物释放到生物组织中磁性脂质体从而释放活化的药物。

5. 发明申请

US20030187047A1 Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents 失效
公开(公告)号：US20030187047A1
公开(公告)日：2003-10-02
申请号：US10393313
申请日：2003-03-19
申请人： Allergan Sales, Inc.
发明人： Stephen A. Munk , James A. Burke , Michael E. Garst
IPC分类号： A61K031/4162 , A61K031/4178 , C07D233/54
CPC分类号： C07D413/12 , C07D233/50 , C07D263/28 , C07D277/18
摘要： A compound of formula I 1 in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower straight or branched chain alkyl of 1 to 6 carbon atoms, or lower straight or branched chain alkenyl of 2 to 6 carbon atoms, a cycloaliphatic ring of 3 to 6 carbon atoms, phenyl optionally mono- or di-substituted with hydroxy, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 2 carbon atoms, or methylenedioxyphenyl; or a stereoisomer, or a pharmaceutically acceptable salt thereof. These compounds have null2 receptor blocking activity and hence find use in the treatment or palliation of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity.

6. 发明申请

US20030144270A1 NK1 antagonists 失效
标题翻译： NK1拮抗剂
公开(公告)号：US20030144270A1
公开(公告)日：2003-07-31
申请号：US10292618
申请日：2002-11-12
申请人： Schering Corporation
发明人： Gregory A. Reichard , Sunil Paliwal , Neng-Yang Shih , Dong Xiao , Hon-Chung Tsui , Sapna Majmundar Shah , Cheng Wang , Michelle Laci Wrobleski
IPC分类号： A61K031/55 , A61K031/445 , A61K031/4162 , A61K031/4025 , A61K031/4015
CPC分类号： C07D207/26 , C07D207/273 , C07D207/38 , C07D401/04
摘要： A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough. 1 wherein the variables are as defined in the specification. A representative compound of the invention is: 2
摘要翻译：具有式（I）的NK1拮抗剂，具有本文定义的变量，其可用于治疗许多障碍，包括呕吐，抑郁，焦虑和咳嗽。其中变量如说明书中所定义。本发明的代表性化合物是：

7. 发明申请

US20020193417A1 Nasal solutions 审中-公开
标题翻译：鼻溶液
公开(公告)号：US20020193417A1
公开(公告)日：2002-12-19
申请号：US10196520
申请日：2002-07-15
发明人： Matthias Seidel , Christopher Buckley
IPC分类号： A61K031/4162 , A61K031/56
CPC分类号： A61K9/0043
摘要： The invention relates to liquid pharmaceutical compositions adapted to nasal administration. The liquid nasal formulations of the invention are characterized inter alia by having excellent and prolonged moisturizing properties.
摘要翻译：本发明涉及适于鼻腔给药的液体药物组合物。本发明的液体鼻制剂的特征在于具有优异且延长的保湿性能。

8. 发明申请

US20020183331A1 Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene 失效
标题翻译： 7,8-二氢-3H-6,9-二氧杂-2,3-二氮杂 - 环戊二烯并[a]萘的抗精神病药物氨基甲基衍生物
公开(公告)号：US20020183331A1
公开(公告)日：2002-12-05
申请号：US10128748
申请日：2002-04-23
申请人： Wyeth
发明人： Megan Tran , Gary P. Stack
IPC分类号： A61K031/496 , A61K031/4709 , A61K031/454 , A61K031/4439 , A61K031/4162
CPC分类号： C07D491/04
摘要： Compounds of the formula: 1 useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced pychoses and dyskinesias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.
摘要翻译：用于治疗多巴胺能系统疾病如精神分裂症，分裂情感障碍，双相情感障碍，帕金森氏病，L-DOPA诱发的嗜酸性细菌和运动障碍，Tourette综合征和高催乳素血症和治疗药物成瘾的化合物，例如成瘾对乙醇，尼古丁或可卡因及相关疾病。

9. 发明申请

US20040106667A1 Substituted indazoles, compositions containing them, method of production and use 有权
标题翻译：取代的吲唑，含有它们的组合物，生产和使用方法
公开(公告)号：US20040106667A1
公开(公告)日：2004-06-03
申请号：US10385870
申请日：2003-03-11
发明人： Dominique Damour , Jean-Christophe Carry , Patrick Nemecek , Corinne Terrier , Frederico Nardi , Bruno Filoche , Marie-Pierre Cherrier , Daniel Bezard
IPC分类号： A61K031/4162
CPC分类号： C07D231/56
摘要： Substituted indazoles, compositions containing them, method of production and use. The present invention relates in particular to novel specific substituted indazoles exhibiting kinase-inhibiting activity, having therapeutic activity, in particlar in oncology.
摘要翻译：取代的吲唑，含有它们的组合物，生产和使用方法。本发明特别涉及具有激酶抑制活性的新型特异性取代吲唑，具有治疗活性，特别是肿瘤学。

10. 发明申请

US20040048866A1 Indazole derivatives that are activators of soluble guanylate cyclase 审中-公开
标题翻译：作为可溶性鸟苷酸环化酶的活化剂的吲唑衍生物
公开(公告)号：US20040048866A1
公开(公告)日：2004-03-11
申请号：US10375842
申请日：2003-02-26
发明人： Teodozyj Kolasa , Jorge D. Brioni , Vijaya Gracias , Masaki Nakane , Meena V. Patel , Jeffrey Rohde
IPC分类号： A61K031/519 , A61K031/502 , A61K031/4745 , A61K031/4162 , C07D471/02 , C07D487/02
CPC分类号： C07D231/56 , C07D401/12 , C07D405/12 , C07D471/04
摘要： Compounds of formula (I) 1 are novel indazoles useful for increasing cGMP levels in a mammal.
摘要翻译：式（I）化合物是用于增加哺乳动物中cGMP水平的新型吲唑。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式